**Appendix Table D12. Clinical outcome information – stroke**

| **Author,year****UID****Country****Study name** | **Treatment** | **Genetic Test Used [index test]** | **Clinical Outcome** | **Outcome Definition** | **Timing of measurement** | **Genotype groups** | **No. with outcome status within phenotype group** | **Comparative metric** | **95% CI** | **P (between which groups?)****[statistical test]** | **Statistical Adjustment****[If YES, for what factors?]** | **Procedures for multiple comparisons** | **Comments** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Mega{Mega, 2009 141 /id} 200919106084MultinationalGenetics substudy of TRITON-TIMI 38 [Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction] | Clopidogrel 300 mg loading dose, 75 mg maintenance | CYP2C19 | Non-fatal stroke | NR; all outcomes were adjudicated by a committee unaware of group assignments | Up to 15 mo (maximum duration of treatment on trial)  | IM or PM (1/\*2A, \*1A/\*3, \*1A/\*4, \*1A/\*8, \*2A/\*2A, \*2A/\*3, \*2A/\*4, \*2A/\*5A, \*2A/\*8)N = 395 | N = NRRate = 0.88% (Kaplan-Meier) | HR = 3.93 | 0.66, 23.51 | NR | ACS subtype (STE or NSTE was used as a stratification factor) | NO | Secondary outcome |
|  |  |  |  |  |  | EM (\*1A/\*1A)N = 1064 | N = NRRate = 0.24% (Kaplan-Meier rate) |  |  |  |  |  |  |
| Sibbing, 2009{Sibbing, 2009 133 /id}19193675GermanyNR | Clopidogrel 600 mg loading dose before stent placement | CYP2C19 \*2 | Ischemic stroke | Confirmed by brain CT or MRI | 30 days  | CYP2C19 \*2 carriers (\*2/\*2 and \*2/\*1)N = 680 | 4 | NR | NR | 0.001 | NO | NO | None |
|  |  |  |  |  |  | CYP2C19 non-carriers (\*1/\*1)N = 1805 | 0 |  |  |  |  |  |  |
| Bonello, 2010{Bonello, 2010 45 /id}20708365FranceNR | All patients received oral LDs of 250 mg aspirin and 600 mg clopidogrel at least 6 h before the first VASP index measurement | CYP2C19 | stroke | stroke | In hospital  | Wild-typeN = 277 | 1 (<1%) | NR | NR | NS | NR | NR | None |
|  |  |  |  |  |  | Heterozygotes 2C19\*2N = 123 | 0 (0%) |  |  |  |  |  |  |
|  |  |  |  |  |  | Homozygotes 2C19\*2N = 11 | 0 (0%) |  |  |  |  |  |  |
| Yamamoto 2011{Yamamoto, 2011 25 /id}21168310JapanNR | clopidogrel | CYP2C19\*2 or \*3 | Ischemic stroke | Ischemic stroke | NR | carriers | 2/62 | NR | NR | NR | NR | NR |  |
|  |  | CYP2C19\*1/\*2 | Stroke | Stroke | 1 days | CYP2C19\*1/\*2 | NR | NR | NR | NR | NR | NR |  |
|  |  |  | Stroke | Stroke | 10 days | CYP2C19\*1/\*2 | NR | NR | NR | NR | NR | NR |  |
|  |  | CYP2C19\*2/\*2 | Cardiovascular death | Cardiovascular death | 74 days | CYP2C19\*2/\*2 | NR | NR | NR | NR | NR | NR |  |
| Tiroch, 2010{Tiroch, 2010 62 /id}20826260GermanyNR | aspirin (100mg twice daily) and clopidogrel ( 75mg once Daily) | CYP2C19\*2 GG | Stroke | Stroke | 1 year  | CYP2C19\*2 GG | 680 | N(%)8(1.2) | NR | 0.085CYP2C19\*2 GG vs \*2 A allele  | NR | NR |  |
|  |  | CYP2C19\*2 A allele | Stroke  | Stroke  | 1 year  | CYP2C19\*2 A allele | 248 | N(%)0(0) | NR |  | NR | NR |  |
|  |  | CYP2C19\*2 GG | Stroke | Stroke | 1 year  | CYP2C19\*2 GG | 565 | N(%)5 (0.9) | NR | 0.93CYP2C19\*17 CC vs T allele | NR | NR |  |
|  |  | CYP2C19\*2 A allele | Stroke  | Stroke  | 1 year  | CYP2C19\*2 A allele | 363 | N(%)3 (0.8) | NR |  | NR | NR |  |
| Luo, 2011{Luo, 2011 18198 /id}22118006ChinaNR | LD clopidogrel 300mg and MD 75mg/d and aspirin 300mg LD and MD 100mg/d | CYP2C19\*1/\*1 | stroke | ischaemic stroke | 6 months | CYP2C19\*1/\*1 | 21/936 | HR 2.23 | 1.18-9.27 | <0.05comparing with the next rowchi-square test  | NR | NR |  |
|  |  | CYP2C19\*1/\*2 or \*2/\*2 |  |  |  | CYP2C19\*1/\*2 or \*2/\*2 | 39/802 |  |  |  |  |  |  |